WO2004099165A3 - Heterocyclic compounds and hydro isomers thereof - Google Patents

Heterocyclic compounds and hydro isomers thereof Download PDF

Info

Publication number
WO2004099165A3
WO2004099165A3 PCT/US2004/013452 US2004013452W WO2004099165A3 WO 2004099165 A3 WO2004099165 A3 WO 2004099165A3 US 2004013452 W US2004013452 W US 2004013452W WO 2004099165 A3 WO2004099165 A3 WO 2004099165A3
Authority
WO
WIPO (PCT)
Prior art keywords
heterocyclic compounds
hydro isomers
hcv
iii
formula
Prior art date
Application number
PCT/US2004/013452
Other languages
French (fr)
Other versions
WO2004099165A2 (en
Inventor
Rajinder Singh
Dane Goff
John J Partridge
Original Assignee
Rigel Pharmaceuticals Inc
Rajinder Singh
Dane Goff
John J Partridge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc, Rajinder Singh, Dane Goff, John J Partridge filed Critical Rigel Pharmaceuticals Inc
Priority to EP04751046A priority Critical patent/EP1620412A2/en
Publication of WO2004099165A2 publication Critical patent/WO2004099165A2/en
Publication of WO2004099165A3 publication Critical patent/WO2004099165A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles

Abstract

The present invention relates to substituted diphenyl heterocycle compounds according to formula (I), (II), (III) and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of the compounds and/or compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections. Formula (I), (II), (III).
PCT/US2004/013452 2003-05-02 2004-04-30 Heterocyclic compounds and hydro isomers thereof WO2004099165A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04751046A EP1620412A2 (en) 2003-05-02 2004-04-30 Heterocyclic compounds and hydro isomers thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46765003P 2003-05-02 2003-05-02
US60/467,650 2003-05-02

Publications (2)

Publication Number Publication Date
WO2004099165A2 WO2004099165A2 (en) 2004-11-18
WO2004099165A3 true WO2004099165A3 (en) 2005-11-03

Family

ID=33435099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/013452 WO2004099165A2 (en) 2003-05-02 2004-04-30 Heterocyclic compounds and hydro isomers thereof

Country Status (3)

Country Link
US (1) US7326790B2 (en)
EP (1) EP1620412A2 (en)
WO (1) WO2004099165A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049065A2 (en) * 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
JP4434818B2 (en) * 2004-03-31 2010-03-17 京セラ株式会社 Error correction method for portable communication terminal and its geomagnetic sensor
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
CN101203498A (en) 2005-05-02 2008-06-18 里格尔药品股份有限公司 Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
UA95907C2 (en) 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
JP2010505870A (en) * 2006-10-03 2010-02-25 アレイ バイオファーマ、インコーポレイテッド Oxadiazole derivatives and thiadiazole derivatives as mitotic kinesin inhibitors and methods for their use
US20080262057A1 (en) * 2007-04-20 2008-10-23 Dow Agrosciences Llc Diarylisoxazolines
EP2411007A4 (en) * 2009-03-27 2012-12-05 Uab Research Foundation Modulating ires-mediated translation
ES2552166T3 (en) 2010-04-12 2015-11-26 Supernus Pharmaceuticals, Inc. Methods for producing viloxazine salts and novel polymorphs thereof
CN112062735B (en) * 2020-09-10 2022-11-08 温州大学 Synthesis method of isoselenazole derivative

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852503A (en) * 1953-12-31 1958-09-16 American Cyanamid Co 2, 5-bis (p-aminophenyl) furan azo derivatives
FR1459375A (en) * 1965-10-20 1966-04-29 Westinghouse Electric Corp Linear oxadiazole-imide copolymers
US3257203A (en) * 1958-08-20 1966-06-21 Azoplate Corp Electrophotographic reproduction material
US3335149A (en) * 1963-08-21 1967-08-08 Monsanto Co Thiazole diamines
DE2137719A1 (en) * 1971-07-28 1973-02-08 Basf Ag Aminobenzonitrile prepn - from halogen - substd triphenylphosphine phenylimines and metal cyanides, esp cuprous cyanide, and hydrolysis
CH559195A5 (en) * 1971-07-22 1975-02-28 Lepetit Spa
US3910942A (en) * 1973-04-02 1975-10-07 Squibb & Sons Inc Anthelmintic (isothiocyanophenyl) oxadiazoles
US3964896A (en) * 1971-08-09 1976-06-22 Uniroyal, Inc. Oxadiazole benzoic acid derivatives as herbicides
DE2721955A1 (en) * 1977-05-14 1978-11-23 Basf Ag AZO DYES
EP0776894A1 (en) * 1994-08-02 1997-06-04 Nippon Soda Co., Ltd. Oxazole derivative, process for producing the same, and herbicide
WO2002055025A2 (en) * 2001-01-13 2002-07-18 Univ North Carolina Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (bvdv) infection and hepatitis c virus (hcv) infection
WO2003040112A1 (en) * 2001-11-02 2003-05-15 Rigel Pharmaceuticals, Inc. Substituted diphenyl heterocycles useful for treating hcv infection
WO2004018463A2 (en) * 2002-08-23 2004-03-04 Rigel Pharmaceuticals, Inc. Pyridyl substituted heterocycles useful for treating or preventing hcv infection
WO2004103366A1 (en) * 2003-05-15 2004-12-02 Rigel Pharmaceuticals Heterocyclic compounds useful to treat hcv

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU35193A1 (en) 1956-06-04
CH392520A (en) 1959-12-30 1965-05-31 Ciba Geigy Process for the preparation of 3'-nitro-4'-hydroxyphenyl-1,3,4-oxdiazoles etherified in the 4'-position
US4087409A (en) 1966-11-07 1978-05-02 Monsanto Company Ordered heterocyclic copolymers
DE2101559C2 (en) 1971-01-14 1982-09-16 Basf Ag, 6700 Ludwigshafen 4-nitro-6-oxadiazolyl- or -6-thiadiazolyl-aniline derivatives
DE2659709C3 (en) 1976-12-31 1982-05-06 Hoechst Ag, 6000 Frankfurt 2,5-bis- (4-aminophenyl) -1,3,4-oxadiazoles and their uses
DE3514182A1 (en) 1985-04-19 1986-10-23 Basf Ag, 6700 Ludwigshafen ELECTROPHOTOGRAPHIC RECORDING MATERIAL
DE3623302A1 (en) 1985-11-09 1987-05-14 Bayer Ag NICOTINE ACID DERIVATIVES
US4777258A (en) 1987-04-23 1988-10-11 The United States Of America As Represented By The Secretary Of The Navy Method for preparing 2,5-dipcryl-1,3,4-oxadiazole
DE4016049A1 (en) 1990-05-18 1991-11-21 Basf Ag 3-ISOXAZOLYLBYL CYLESTER, THEIR PRODUCTION AND USE
JPH04124178A (en) 1990-09-12 1992-04-24 Sds Biotech Kk Heterocyclic compound and herbicide containing the same
DE4124942A1 (en) 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING SUCH COMPOUNDS
DE4137940A1 (en) 1991-11-18 1993-05-19 Basf Ag 3-ISOXAZOLYLPHENYL COMPOUNDS, THEIR PRODUCTION AND THEIR USE
JPH07508504A (en) 1992-03-06 1995-09-21 リーカ　ファーマシュティカルズ　エイ／エス Prevention and treatment of diseases caused by parasites or bacteria
DE4210502A1 (en) 1992-03-31 1993-10-07 Bayer Ag Use of 3-amino-substituted isoxazole derivatives for the control of endoparasites, new 3-amino-substituted isoxazole derivatives and processes for their preparation
JPH06184147A (en) 1992-12-18 1994-07-05 Asahi Glass Co Ltd Isoxazole derivative
WO1994017059A1 (en) 1993-01-29 1994-08-04 Nippon Soda Co., Ltd. Heterocyclic derivative
DE4408084A1 (en) 1994-03-10 1995-09-14 Hoechst Ag 3,5-disubstituted and 3,4,5-trisubstituted 2-isoxazolines and isoxazoles, processes for their preparation and their use as medicaments
DE19643037A1 (en) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg New oxadiazoles, processes for their preparation and their use as medicines
EP2409985A3 (en) 1996-10-18 2013-05-01 Vertex Pharmaceuticals Incorporated Inhibitors de serine proteases, especially of the NS3 protease of the hepatitis C virus
US20020035156A1 (en) 1997-04-18 2002-03-21 Barbara Roniker Combination therapy in the prevention of cardiovascular disorders
GEP20022812B (en) 1997-04-18 2002-10-25 Searle & Co Using Cyclooxygenase-2 Inhibitors for Preparing Medicinal Means to Prevent Cardiovascular Disorders Connected with Inflammation Processes and Pharmaceutical Compositions Containing These Inhibitors
CN1239570A (en) 1997-07-17 1999-12-22 索尼公司 Magnetic recording mediumand magnetic recorder/reproducer comprising same
WO1999020309A1 (en) 1997-10-22 1999-04-29 Eisai Co., Ltd. Retinoic acid agonists as preventive and therapeutic agents for nephritis
DE19860802A1 (en) 1998-12-30 2000-10-26 Virgene Pharmaceuticals Ag Production of an agent against hepatitis B, HI, Paramyxo and Orthomyxo viruses
DE19904389A1 (en) 1999-02-04 2000-08-10 Bayer Ag Use of substituted isoxazolecarboxylic acids and derivatives and new substances
RU2237062C2 (en) 1999-04-23 2004-09-27 Такеда Кемикал Индастриз, Лтд. Derivatives of 5-pyridyl-1,3-azole, method for their preparing, their prodrug, pharmaceutical composition, method for antagonism of adenosine a3-receptor, method for inhibition of p38 map kinase, method for inhibition producing tnf-alpha and method for prophylaxis
GB2351081A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
DE10032874A1 (en) 2000-07-06 2002-01-17 Bayer Ag New 4-substituted 3,5-dialkyl-isoxazole derivatives, useful as antiviral agents having strong activity against hepatitis B virus and low cytotoxicity
HUP0300850A2 (en) * 2000-03-17 2003-07-28 Bristol-Myers Squibb Pharma Company Cyclic betha-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha and pharmaceutical compositions containing them and their use
US7495018B2 (en) 2000-03-30 2009-02-24 Takeda Pharmaceutical Company Limited Substituted 1,3-thiazole compounds, their production and use
US6608058B2 (en) 2000-04-17 2003-08-19 Dong Wha Pharm. Ind. Co., Ltd. 6-methylnicotinamide derivatives as antiviral agents
US6579880B2 (en) 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
US20020077491A1 (en) 2000-09-05 2002-06-20 Shipps Gerald W. Methods for forming combinatorial libraries combining amide bond formation with epoxide opening
JP2002146048A (en) 2000-11-07 2002-05-22 Idemitsu Petrochem Co Ltd Polyolefinic decoration sheet
CA2431171A1 (en) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
DE10148598A1 (en) 2001-04-19 2002-10-24 Bayer Ag New N-(acylaminophenyl)-heteroaryl-benzenesulfonamide derivatives, useful as antiviral agents, especially effective against human cytomegalovirus infections
JP4303109B2 (en) 2001-10-04 2009-07-29 メルク エンド カムパニー インコーポレーテッド Heteroaryl-substituted tetrazole modulator of metabotropic glutamate receptor-5
JP2003122652A (en) 2001-10-10 2003-04-25 Sony Corp Communication system and communication method, server device and electronic equipment
WO2004099164A1 (en) 2003-05-02 2004-11-18 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852503A (en) * 1953-12-31 1958-09-16 American Cyanamid Co 2, 5-bis (p-aminophenyl) furan azo derivatives
US3257203A (en) * 1958-08-20 1966-06-21 Azoplate Corp Electrophotographic reproduction material
US3335149A (en) * 1963-08-21 1967-08-08 Monsanto Co Thiazole diamines
FR1459375A (en) * 1965-10-20 1966-04-29 Westinghouse Electric Corp Linear oxadiazole-imide copolymers
CH559195A5 (en) * 1971-07-22 1975-02-28 Lepetit Spa
DE2137719A1 (en) * 1971-07-28 1973-02-08 Basf Ag Aminobenzonitrile prepn - from halogen - substd triphenylphosphine phenylimines and metal cyanides, esp cuprous cyanide, and hydrolysis
US3964896A (en) * 1971-08-09 1976-06-22 Uniroyal, Inc. Oxadiazole benzoic acid derivatives as herbicides
US3910942A (en) * 1973-04-02 1975-10-07 Squibb & Sons Inc Anthelmintic (isothiocyanophenyl) oxadiazoles
DE2721955A1 (en) * 1977-05-14 1978-11-23 Basf Ag AZO DYES
EP0776894A1 (en) * 1994-08-02 1997-06-04 Nippon Soda Co., Ltd. Oxazole derivative, process for producing the same, and herbicide
WO2002055025A2 (en) * 2001-01-13 2002-07-18 Univ North Carolina Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (bvdv) infection and hepatitis c virus (hcv) infection
WO2003040112A1 (en) * 2001-11-02 2003-05-15 Rigel Pharmaceuticals, Inc. Substituted diphenyl heterocycles useful for treating hcv infection
WO2004018463A2 (en) * 2002-08-23 2004-03-04 Rigel Pharmaceuticals, Inc. Pyridyl substituted heterocycles useful for treating or preventing hcv infection
WO2004103366A1 (en) * 2003-05-15 2004-12-02 Rigel Pharmaceuticals Heterocyclic compounds useful to treat hcv

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"MAYBRIDGE HTS, ORDER NUMBER BTB 09742; RN 247059-16-1", MAYBRIDGE PLC, TREVILLETT, TINTAGEL, CORNWALL, PL34OHW, UK, 8 January 2004 (2004-01-08), XP002297442 *
DATABASE CHEMCATS [online] 1999, XP002310049, retrieved from STN Database accession no. RN 247059-16-1 *

Also Published As

Publication number Publication date
US7326790B2 (en) 2008-02-05
WO2004099165A2 (en) 2004-11-18
US20040254227A1 (en) 2004-12-16
EP1620412A2 (en) 2006-02-01

Similar Documents

Publication Publication Date Title
CA2473070A1 (en) Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection
EP1924593B8 (en) Hcv ns3 protease inhibitors
WO2004002940A8 (en) Inhibitors of hcv ns5b polymerase
WO2007112028A3 (en) 2'-fluoronucleoside phosphonates as antiviral agents
WO2008057208A3 (en) Hcv ns3 protease inhibitors
WO2008051475A3 (en) Hcv ns3 protease inhibitors
WO2008051477A3 (en) Hcv ns3 protease inhibitors
WO2007009109A3 (en) Antiviral compounds
MY151199A (en) Substituted diphenyl heterocycles useful for treating hcv infection
WO2005051980A8 (en) Depeptidized inhibitors of hepatitis c virus ns3 protease
MY164469A (en) Hcv ns3 protease inhibitors
WO2004041201A3 (en) Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
WO2004106293A3 (en) Oxazolyl - and thiazolyl - purine based tricyclic compounds.
WO2009023179A3 (en) Nitrogen containing bicyclic chemical entities for treating viral infections
EP2431379A3 (en) HCV inhibitors
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
NO20073105L (en) pyridazinone
WO2008079159A3 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
WO2007133865A3 (en) Hcv/hiv inhibitors an their uses
WO2008008907A3 (en) Antiviral agents
WO2007120374A3 (en) Anti-arenaviral compounds
WO2004112718A3 (en) Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
WO2004099165A3 (en) Heterocyclic compounds and hydro isomers thereof
WO2004075846A3 (en) Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004751046

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004751046

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)